North America Europe Infectious Disease Molecular Diagnostics Market Report: Market Size & Forecast 2026

The North American infectious disease molecular diagnostics market focuses on DNA and RNA-based testing platforms that identify pathogens with high sensitivity and specificity, enabling faster and more accurate clinical decision-making compared to traditional culture or serological methods. Key technologies include real-time PCR, multiplex assays, and emerging CRISPR-based diagnostics, serving hospitals, reference laboratories, point-of-care settings, and public health institutions across the United States, Canada, and Mexico.

• •Market valued at $11.08 billion in 2025 with a projected CAGR of 6.91% through the early 2030s
• •North America accounts for the largest regional share of the global infectious disease molecular diagnostics market
• •Driven by demand for rapid, accurate pathogen detection and antimicrobial resistance monitoring

The market expansion is propelled by increasing incidence of infectious diseases including COVID-19 variants, influenza, respiratory syncytial virus, and sexually transmitted infections, alongside growing awareness of antimicrobial resistance requiring molecular-level surveillance. Technological miniaturization enabling point-of-care molecular testing, reimbursement policy improvements, and expanded laboratory infrastructure have further accelerated adoption across clinical settings.

• •Rising prevalence of chronic and emerging infectious diseases across North American populations
• •Technological advancements in PCR, NGS, and rapid molecular platforms improving speed and accessibility
• •Favorable regulatory approvals and growing healthcare expenditure supporting diagnostic innovation

The market segments by product type into instruments, reagents and consumables, and software services, with reagents and consumables representing the largest revenue share due to recurring demand. By application, the market covers disease areas including COVID-19, HIV, hepatitis, tuberculosis, and hospital-acquired infections. The United States dominates the regional landscape, followed by Canada, with Mexico showing emerging growth potential due to expanding healthcare modernization efforts.

• •Reagents and consumables segment leads due to continuous testing requirements and assay repeat purchases
• •Hospital and clinical laboratory settings account for the majority of end-user demand
• •United States represents the primary market hub, supported by advanced healthcare infrastructure and R&D investment

What are the recent trends and outlook?

Emerging trends include the integration of artificial intelligence for pathogen identification and antimicrobial resistance prediction, increased adoption of syndromic panels enabling simultaneous detection of multiple pathogens, and the expansion of at-home and decentralized molecular testing options. Future growth is expected to be supported by pandemic preparedness initiatives, investments in genomic surveillance infrastructure, and the development of portable, affordable molecular devices for point-of-care use in diverse healthcare settings.

• •Syndromic testing panels combining multiple pathogen targets gaining adoption in hospital and urgent care settings
• •Point-of-care molecular diagnostics expanding beyond traditional laboratory environments to pharmacies and remote locations
• •Integration of next-generation sequencing and bioinformatics enhancing outbreak detection and epidemiological surveillance capabilities